PRTODAY / NewswireToday Free press release distribution service network

Written by / Agency / Source: ECON Corporate Services / InvestorIdeas.com™

Check Ads Availability|e-mail Article


Are you the owner of this article?, Turn it PREMIUM with your LOGO instead - and make it 3rd party Ads-Free! within the next hour!

China-AsiaStocks.com Reports on Healthcare Opportunities in China - Benda Pharmaceutical capitalizes on accelerated healthcare spending in China and growing opportunities for Gendicine® cancer treatment (OTCBB: BPMA)
China-AsiaStocks.com Reports on Healthcare Opportunities in China

 

NewswireToday - /newswire/ - Point Roberts, WA, United States, 2008/02/04 - Benda Pharmaceutical capitalizes on accelerated healthcare spending in China and growing opportunities for Gendicine® cancer treatment (OTCBB: BPMA).

   
 
Your Banner Ad Here instead - Showing along with ALL Articles covering Brokerage/Trading Announcements

Replace these Affiliate Programs at ANYTIME! Your banner here within the next hour. Learn How!


 

China-AsiaStocks.com, an investor and industry portal focused on the China-Asia sector within Investorideas.com, reports on the growing Chinese healthcare market opportunities, with focus on featured company, Benda Pharmaceutical Inc.(OTCBB:BPMA). The globalization and blending of western and traditional medicine is a growing trend, prevalent in China but also on the rise in North America.

Benda Pharmaceutical is a China-based pharmaceutical company producing both Gendicine®, the world’s first commercialized gene therapy medicine for the treatment of cancer, and traditional Chinese and conventional medicines. The company recently launched a new investor video to provide investors insight into the Benda and Gendicine® investment opportunity.

The company video showcases key investment facts, including revenue growth from $15.9 million in 2006, to projected revenue of $56 million in 2008. Healthcare spending in China is anticipated to grow to $323 billion by 2025 and is a driving force in Benda’s projections. Recent announcements by the Chinese government to attempt to tighten control of costs for medical services and drugs heighten awareness to the growing issue.

The rapidly growing healthcare market in China, with an aging and more affluent population, will incite new entrants and new technologies. To be competitive, technologies and products will need to prove claims and meet regulatory standards. According to Benda’s video, the company’s cancer treatment technology is 340% more effective than traditional treatments.

Other public companies capitalizing on the China healthcare opportunity include Beijing Med-Pharm Corporation a pharmaceutical marketing and distribution company that is building a proprietary portfolio of branded pharmaceutical and healthcare products in China.
Linkwell Corporation develops, manufactures, and distributes disinfectant healthcare products in China, estimated at $6.25 Billion, according to recent press from the company.

Other Biotech Companies competing for the cancer treatment market in China include BioSphere Medical, Inc. a medical device company that uses bioengineered microspheres to treat uterine fibroids, hypervascularized tumors, and vascular malformations by a minimally invasive, image-guided medical procedure called embolotherapy. The company announced the Medical Device Department of the State Food and Drug Administration of the People’s Republic of China has approved BioSphere’s Embosphere Microspheres for clinical use for vascular embolizations, arteriovenous malformations, hypervascularized tumors, and symptomatic uterine fibroids and expects to begin shipments of Embosphere Microspheres to China in the first quarter of 2008.

According to a Decision Resources report published in 2007, pharmaceutical and healthcare industry analysts predict that the Chinese hepatocellular carcinoma (HCC; the most prevalent type of primary liver cancer) market will quadruple between 2006 and 2011.CELSION CORPORATION recently announced that its application for a Special Protocol Assessment (SPA) for its Pivotal Phase III Primary Liver Cancer trial has been agreed to by the US Food and Drug Administration, to demonstrate the efficacy of Celsion’s proprietary chemotherapeutic, ThermoDox, in combination with radiofrequency ablation as a first line treatment of primary liver cancer. The study will incorporate about 40 clinical sites in North America, Italy, China, Taiwan, Hong Kong, and Korea, and is planned to enroll 600 patients.

About Benda Pharmaceutical, Inc.
Benda Pharmaceutical, Inc., a China-based pharmaceutical company, is a pure play on explosive Chinese pharmaceutical spending and the global search for a cancer cure. Benda produces traditional Chinese and conventional medicines, as well as Gendicine®, the world’s first commercialized gene therapy medicine for the treatment of cancer.

About InvestorIdeas.com:
InvestorIdeas.com is a leading global investor and industry research resource portal specialized in sector investing covering over thirty industry sectors and global markets including China, India, Middle East and Australia.

InvestorIdeas.com Disclaimer:. Our sites do not make recommendations, but offer information portals. Nothing on our sites should be construed as an offer or solicitation to buy or sell products or securities. All Information relating to featured companies is sourced from public documents and/ or the company and is not the opinion of our web sites. Disclosure: Benda Pharmaceutical, Inc. (OTCBB: BPMA) compensates the site $4000USD per month as a showcase company.

Source: China-AsiaStocks.com, Benda Pharmaceutical, Inc.

 
 
Your Banner Ad Here instead - Showing along with ALL Articles covering Brokerage/Trading Announcements

Replace these Affiliate Programs at ANYTIME! Your banner here within the next hour. Learn How!


 

Written by / Agency / Source: ECON Corporate Services / InvestorIdeas.com™

 
 

Availability: All Regions (Including Int'l)

 

Traffic Booster: [/] Quick Newswire Today Visibility Checker

 

Distribution / Indexing: [+]

 
 
# # #
 
 
  Your Banner Ad showing on ALL
Brokerage/Trading articles,
CATCH Visitors via Your Competitors Announcements!


China-AsiaStocks.com Reports on Healthcare Opportunities in China

Company website links NOT available to basic submissions
It is OK to republish and/or LINK any newswire for any legitimate media purpose as long as you name Newswire Today and LINK as the source.
 
  Is this your article?
Activate ALL web links and social stream by Upgrading to Press Release PREMIUM Plan Now!

|
Publisher Contact: Dawn Van Zant 
800-665-0411 dvanzant[.]investorideas.com
 
Newswire Today - PRZOOM / PRTODAY disclaims any content contained in this article. If you need/wish to contact the company who published the current release, you will need to contact them - NOT us. Issuers of articles are solely responsible for the accuracy of their content. Our complete disclaimer appears here.
IMPORTANT INFORMATION: Issuance, publication or distribution of this press release in certain jurisdictions could be subject to restrictions. The recipient of this press release is responsible for using this press release and the information herein in accordance with the applicable rules and regulations in the particular jurisdiction. This press release does not constitute an offer or an offering to acquire or subscribe for any ECON Corporate Services / InvestorIdeas.com™ securities in any jurisdiction including any other companies listed or named in this release.

Brokerage/Trading via RSSAdd NewswireToday - PRZOOM Headline News to FeedBurner
Find who RetweetFollow @NewswireTODAY



Are you the owner of this article?, Turn it PREMIUM with your LOGO instead - and make it 3rd party Ads-Free! within the next hour!


Read Latest Articles From ECON Corporate Services / InvestorIdeas.com™ / Company Profile


Read Brokerage/Trading Most Recent Related Newswires:

SRMEX's Vice Chairman Eikichi Hirano About the Gradual Expansion of Capital Market
Xtrade Wins Best Broker in the Middle East Award
Russian Foreign Trade Reports on Russian Trade with North American Countries Q1 2016
DarkMaindFX Introduces the Beta Version of its Economic Indicator Services
Hermes International Expo to Celebrate 25th Anniversary in Delaware County
GoldSilver Central Approved As Singapore Bullion Market Association Member
OANDA Acquires Tradestation Forex Accounts
[TYPO FOUND BY SYSTEM] Beeline Broking Ltd Launches 'Tailor Made Brokerage Plan'
Signals365.com Announces Key Features - Makes it the Best Binary Options Signals Service
Binary Options Signals from Signals365.com Helps Traders to Get Higher Win-Rate
/RC/ Van Ecker Couder Associates Announce Expansion Program
/RC/ Voth Nixon Group Bolsters Deferred Income Annuity
Grant Becker Associates Chalks Up Another Successful Year of CSR Activities
Evanson Asset Management Dividend Stocks to Safeguard An All-weather Portfolio
AKFinancials Announces its 2015 Forex Course Schedule

Boost Your Social Network
& Crowdfunding Campaigns


LIFETIME SOCIAL MEDIA WALL
NewswireToday Celebrates 10 Years in Business


PREMIUM Members


Visit  JobsWare.com

Visit  BizJobs.com





 
  ©2016 Newswire Today — Limelon Advertising, Co.
Home | About | Advertise/Pricing | Contact | Investors | Privacy/TOS | Sitemap | FRANCAIS
newswire, PR free press releases distribution service magazines engine news alert newsroom press room breaking news public relations articles company news alerts newswiredistribution ezine bizentrepreneur biznewstoday digital business report market search pr firms agencies reports distri-bution today investor relation successful internet entrepreneurs newswire distribution prtoday.com freenewswiredistribution asianewstoday bizwiretoday USA pr UK today - NOT affiliated with PRNewswire as we declined their partnership offer in 2013
 
PRTODAY & NewswireTODAY are NOT affiliated with USA TODAY (usatoday.com)